Tricyclic azaindolizine derivatives having an sPLA2-inhibitory activities
US6756376B1 · kind B1 · utility
1Cited by
1References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 9, 2002 |
| Grant date | Jun 29, 2004 |
| Priority date | — |
| Expiry date | Jun 26, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound having sPLA2 inhibiting activity.The compound represented by the formula (I): wherein E is N or C—R4; G is N or C—R25; R1 is a carbocyclic group, heterocyclic group or the like; one of R3 and R4 is —(L2)-(acidic group), the other is a hydrogen atom, wherein L2 is a group connecting with an acid group; A ring is optionally substituted 5-8 membered cyclohexane ring or cyclohexene ring; R24 and R25 are a hydrogen atom or the like,its prodrug, their pharmaceutically acceptable salt, or hydrate thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.